This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	MicroRNA-380-5p (miR-380-5p)	<p>Studies in patient samples and in mice suggest that antagonizing miR-380-5p could help treat neuroblastoma. About 76% of primary neuroblastoma samples showed miR-380-5p overexpression relative to expression in normal brain tissue. In a mouse neuroblastoma model, twice-weekly injections of chemically modified anti-miR-380-5p oligonucleotides significantly decreased tumor size and weight compared with injection of control oligonucleotides ($p=0.01$). Next steps include identifying other tumors in which antagonizing miR-380-5p could have a therapeutic effect. Regulus Therapeutics Inc. has miRNA-targeting compounds in preclinical development for multiple indications including cancer.</p> <p>SciBX 3(39); doi:10.1038/scibx.2010.1177 Published online Oct. 7, 2010</p>	Work unpatented; licensing status not applicable	<p>Swarbrick, A. <i>et al. Nat. Med.</i>; published online Sept. 21, 2010; doi:10.1038/nm.2227</p> <p>Contact: Andrei Goga, University of California, San Francisco, Calif. e-mail: andrei.goga@ucsf.edu</p> <p>Contact: Alexander Swarbrick, Garvan Institute, Sydney, New South Wales, Australia e-mail: a.swarbrick@garvan.org.au</p>